A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02162719 |
Recruitment Status
:
Active, not recruiting
First Posted
: June 13, 2014
Last Update Posted
: March 20, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Neoplasms | Drug: Ipatasertib Drug: Paclitaxel Drug: Placebo | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 124 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer |
Actual Study Start Date : | September 30, 2014 |
Actual Primary Completion Date : | June 6, 2016 |
Estimated Study Completion Date : | August 1, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Ipatasertib + Paclitaxel
Participants will receive ipatasertib and paclitaxel in cycles of 28 days (4 weeks) each and study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
|
Drug: Ipatasertib
Participants will receive ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
Other Name: GDC-0068
Drug: Paclitaxel
Participants will receive paclitaxel 80 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
|
Placebo Comparator: Placebo + Paclitaxel
Participants will receive placebo and paclitaxel in cycles of 28 days (4 weeks) each and study treatment will continue until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
|
Drug: Paclitaxel
Participants will receive paclitaxel 80 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
Drug: Placebo
Participants will receive oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
|
- PFS in All Participants, as Assessed by Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST), Version (v) 1.1 [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 2.5 years) ]
- PFS in Participants with PTEN-Low Tumors, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 2.5 years) ]
- Percentage of Participants with Adverse Events [ Time Frame: Baseline up to approximately 2.5 years ]
- Steady State Area Under the Concentration Time Curve from Time Zero to 24 Hours (AUC0-24) of Ipatasertib [ Time Frame: 0.5-2 hours and 4-6 hours post-ipatasertib oral dose on Cycle 1 Day 1 (cycle length=28 days); 0-2 hours and 2-5 hours post-ipatasertib oral dose on Cycle 1 Day 8 ]
- Overall Survival (OS) in All Participants [ Time Frame: Baseline up to death due to any cause (up to approximately 2.5 years) ]
- OS in Participants with PTEN-Low Tumors [ Time Frame: Baseline up to death due to any cause (up to approximately 2.5 years) ]
- OS in Participants with Phosphoinositol 3 Kinase (PI3k)/Protein Kinase B (Akt) Pathway Activated Tumors [ Time Frame: Baseline up to death due to any cause (up to approximately 2.5 years) ]
- Apparent Clearance Following Oral Dosing (CL/F) of Ipatasertib [ Time Frame: 0.5-2 hours and 4-6 hours post-ipatasertib oral dose on Cycle 1 Day 1 (cycle length=28 days); 0-2 hours and 2-5 hours post-ipatasertib oral dose on Cycle 1 Day 8 ]
- European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Score [ Time Frame: Day 1 of each 28-day cycle, at treatment completion/early discontinuation (up to approximately 2.5 years), at tumor follow-up and unscheduled adverse event follow-up (up to approximately 2.5 years overall) ]
- Percentage of Participants With Protocol Defined Bothersome Treatment-Related Symptoms [ Time Frame: Baseline up to approximately 2.5 years ]
- Percentage of Participants with Confirmed Objective Tumor Response (Complete Response [CR] or Partial Response [PR]) in All Participants with Measurable Disease at Baseline, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 2.5 years) ]
- Percentage of Participants with Confirmed Objective Tumor Response (CR or PR) in Participants with Measurable Disease at Baseline and PTEN-Low Tumors, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 2.5 years) ]
- Percentage of Participants with Confirmed Objective Tumor Response (CR or PR) in All Participants with Measurable Disease at Baseline and PI3K/Akt Pathway Activated Tumors, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 2.5 years) ]
- Duration of Confirmed Objective Response in Participants with Measurable Disease at Baseline, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 2.5 years) ]
- Duration of Confirmed Objective Response in Participants with Measurable Disease at Baseline and PTEN-Low Tumors, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 2.5 years) ]
- Duration of Confirmed Objective Response in Participants with Measurable Disease at Baseline and PI3K/Akt Pathway Activated Tumors, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 2.5 years) ]
- Time to Disease Progression in Participants with Measurable Disease at Baseline, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression (up to approximately 2.5 years) ]
- Time to Disease Progression in Participants with Measurable Disease at Baseline and PTEN-Low Tumors, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression (up to approximately 2.5 years) ]
- Time to Disease Progression in Participants with Measurable Disease at Baseline and PI3K/Akt Pathway Activated Tumors, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression (up to approximately 2.5 years) ]
- PFS in All Participants with Measurable Disease at Baseline and PI3K/Akt Pathway Activated Tumors, as Assessed by Investigator Based on RECIST v1.1 [ Time Frame: Baseline up to disease progression or death due to any cause whichever occurs first (up to approximately 2.5 years) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically documented triple-negative adenocarcinoma of the breast that is inoperable locally advanced or metastatic and is not amenable to resection with curative intent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor specimen, required prior to randomization
- Measurable disease, according to the RECIST v1.1
- Adequate hematologic and organ function within 14 days before the first study treatment
- For female participants of childbearing potential, agreement (by both participant and partner) to use an effective form of contraception for the duration of the study and for 6 months after last dose of study treatment
Exclusion Criteria:
- Any previous therapy, including chemotherapy or hormonal or targeted therapy, for inoperable locally advanced or metastatic triple-negative adenocarcinoma of the breast. Participants may have received prior neoadjuvant or adjuvant chemotherapy and/or radiation treatment for locally advanced triple negative adenocarcinoma, provided all treatments were completed greater than or equal to (>/=) 6 months prior to Cycle 1 Day 1. Locally recurrent disease must not be amenable to resection with curative intent
- Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1
- Known Human Epidermal Growth Factor Receptor 2 (HER2) positive, erythrocyte receptor (ER) positive, or progesterone receptor (PR) positive breast cancer
- Previous therapy with Akt, PI3K, and/or mTOR inhibitors
- Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study
- Known presence of the brain or spinal cord metastasis, as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or prior radiographic assessments

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02162719

Study Director: | Clinical Trials | Hoffmann-La Roche |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Genentech, Inc. |
ClinicalTrials.gov Identifier: | NCT02162719 History of Changes |
Other Study ID Numbers: |
GO29227 2014-000469-35 ( EudraCT Number ) |
First Posted: | June 13, 2014 Key Record Dates |
Last Update Posted: | March 20, 2018 |
Last Verified: | March 2018 |
Additional relevant MeSH terms:
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel Albumin-Bound Paclitaxel |
Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |